| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CR2 |
| Uniprot No | P20023-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-971aa |
| 氨基酸序列 | MGAAGLLGVF LALVAPGVLG ISCGSPPPIL NGRISYYSTP IAVGTVIRYS CSGTFRLIGE KSLLCITKDK VDGTWDKPAP KCEYFNKYSS CPEPIVPGGY KIRGSTPYRH GDSVTFACKT NFSMNGNKSV WCQANNMWGP TRLPTCVSVF PLECPALPMI HNGHHTSENV GSIAPGLSVT YSCESGYLLV GEKIINCLSS GKWSAVPPTC EEARCKSLGR FPNGKVKEPP ILRVGVTANF FCDEGYRLQG PPSSRCVIAG QGVAWTKMPV CEEIFCPSPP PILNGRHIGN SLANVSYGSI VTYTCDPDPE EGVNFILIGE STLRCTVDSQ KTGTWSGPAP RCELSTSAVQ CPHPQILRGR MVSGQKDRYT YNDTVIFACM FGFTLKGSKQ IRCNAQGTWE PSAPVCEKEC QAPPNILNGQ KEDRHMVRFD PGTSIKYSCN PGYVLVGEES IQCTSEGVWT PPVPQCKVAA CEATGRQLLT KPQHQFVRPD VNSSCGEGYK LSGSVYQECQ GTIPWFMEIR LCKEITCPPP PVIYNGAHTG SSLEDFPYGT TVTYTCNPGP ERGVEFSLIG ESTIRCTSND QERGTWSGPA PLCKLSLLAV QCSHVHIANG YKISGKEAPY FYNDTVTFKC YSGFTLKGSS QIRCKADNTW DPEIPVCEKE TCQHVRQSLQ ELPAGSRVEL VNTSCQDGYQ LTGHAYQMCQ DAENGIWFKK IPLCKVIHCH PPPVIVNGKH TGMMAENFLY GNEVSYECDQ GFYLLGEKKL QCRSDSKGHG SWSGPSPQCL RSPPVTRCPN PEVKHGYKLN KTHSAYSHND IVYVDCNPGF IMNGSRVIRC HTDNTWVPGV PTCIKKAFIG CPPPPKTPNG NHTGGNIARF SPGMSILYSC DQGYLLVGEA LLLCTHEGTW SQPAPHCKEV NCSSPADMDG IQKGLEPRKM YQYGAVVTLE CEDGYMLEGS PQSQCQSDHQ WNPPLAVCRS R |
| 预测分子量 | 106 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CR2重组蛋白的3篇文献示例(内容为虚构模拟)：
1. **《Structural analysis of recombinant CR2 in B-cell signaling》**
- 作者：Smith, J. et al.
- 摘要：通过重组表达人源CR2胞外域蛋白，解析其晶体结构，揭示CR2与补体片段C3d的结合机制，为调控B细胞免疫应答提供结构基础。
2. **《CR2-targeted recombinant protein alleviates lupus nephritis in murine models》**
- 作者：Wang, L. et al.
- 摘要：开发CR2重组融合蛋白(CR2-FH)，靶向递送补体调控因子至肾脏炎症部位，显著减轻狼疮小鼠模型的肾损伤和自身免疫反应。
3. **《CR2 recombinant protein enhances antigen delivery in vaccine design》**
- 作者：Garcia, R. et al.
- 摘要：利用CR2重组蛋白与抗原偶联，证明其可通过结合B细胞表面CR2受体，提升疫苗的抗原呈递效率，增强小鼠模型中的抗体应答。
注：以上文献为示例，实际文献需通过PubMed、Google Scholar等平台检索确认。
CR2 (Complement Receptor type 2), also known as CD21. is a membrane glycoprotein primarily expressed on B lymphocytes, follicular dendritic cells, and certain epithelial cells. It plays a critical role in the adaptive immune response by binding complement fragments like C3d, which opsonize antigens, enhancing B cell receptor (BCR)-mediated antigen recognition and immune synapse formation. CR2 forms a coreceptor complex with CD19 and CD81. amplifying B cell activation signals and promoting humoral immunity. Additionally, CR2 serves as the cellular receptor for Epstein-Barr virus (EBV), facilitating viral entry and latent infection.
Recombinant CR2 proteins are engineered through genetic techniques, often expressed in mammalian (e.g., CHO cells) or bacterial systems. These proteins typically retain functional domains, such as the short consensus repeats (SCRs) responsible for ligand binding. Recombinant CR2 has become a valuable tool for studying immune regulation, pathogen-host interactions, and complement system dynamics. It is also explored therapeutically, including in targeting autoimmune diseases (e.g., lupus), cancers (e.g., B cell malignancies), and infectious diseases by modulating complement pathways or blocking EBV entry. Furthermore, CR2 fusion proteins are designed to deliver drugs or imaging agents specifically to CR2-expressing cells, improving therapeutic precision. Research into CR2 structure-function relationships and its role in disease models continues to advance its potential in immunotherapy and diagnostics.
×
